Abecma denied for missing prior authorization by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Abecma

Abecma (idecabtagene vicleucel) is a one-time CAR-T cell therapy for multiple myeloma administered at specialized treatment centers. Because of its complexity and cost, Humana — like virtually all major insurers — requires prior authorization before infusion. A denial labeled "prior-auth-required" most often means authorization was not obtained before the service, was obtained for a different indication or patient, or lapsed. In some cases it means a retroactive authorization request was denied. Understanding exactly which scenario applies shapes the appeal strategy.

## Your Right to Appeal

Even retroactive prior-authorization denials are appealable. Under ACA §2719 and ERISA §503, you have rights to internal appeal and independent external review. External review must typically be requested within four months of your final internal denial. If treatment is urgent and not yet administered, an expedited prior-authorization appeal (72-hour decision) is available. For emergencies, a concurrent expedited appeal may also apply if infusion has already begun at an authorized center.

## Building Your Appeal

1. Clarify the exact denial basis — request the full denial letter and the clinical criteria Humana applied. Determine whether the denial is: (a) no prior auth was obtained, (b) auth was obtained but for wrong indication/dates, or (c) retroactive auth was denied. 2. Diagnosis and eligibility documentation — gather pathology reports, bone marrow biopsy results, imaging, and complete prior treatment history with dates and outcomes, showing the patient meets the authorized indication per both the FDA prescribing label and Humana's CAR-T coverage policy. 3. Treating center credentials — Abecma must be administered at a certified REMS site. Document that the administering facility is REMS-certified and that the prescribing physician is qualified, as Humana's policy may require this. 4. Prescriber letter — the treating oncologist should write a letter citing each criterion in Humana's prior-authorization policy and mapping it to a chart-documented fact, and explaining the clinical urgency if applicable. 5. Billing and administrative review — confirm with the treatment center that the correct HCPCS and revenue codes were submitted and that the authorization request referenced the correct NPI and facility.

## Criteria-Mapping Structure

Obtain Humana's published prior-authorization criteria for CAR-T therapies. Create a two-column table: left column lists each criterion verbatim; right column cites the date and source document in the chart that satisfies it. This structured format makes it harder for a reviewer to overlook documented eligibility.